Bcl-2兔多克隆抗体
发表时间:2025-07-22Bcl-2兔多克隆抗体
引言
Bcl-2(B细胞淋巴瘤-2)是凋亡调控的关键蛋白,其异常表达与肿瘤发生、耐药性及代谢疾病密切相关。Bcl-2兔多克隆抗体作为重要研究工具,广泛应用于基础机制探索和临床诊断领域[1][2][3]。
一、抗体的基础特性
1. 分子结构与来源
- 靶点特异性:识别Bcl-2蛋白的保守表位(如BH3结构域),与Bax、Bad等凋亡相关蛋白无交叉反应[3][4]。
2. 实验应用参数
- Bcl-2抗体货号:APRab07501
- 种属反应性:Human,Mouse,Rat,Chicken
- 应用范围:WB,IHC-P,IF-P,IF-F,ICC/IF,ELISA
- 稀释比:WB 1:500-1:2000, IHC-P 1:100-1:300, IF-P/IF-F/ICC/IF 1:200-1:1000, ELISA 1:10000.Not yet tested in other applications.
- 蛋白分子量:26 kDa.[5]
二、作用机制研究中的应用
1. 凋亡通路调控
- 抑制凋亡:Bcl-2高表达阻断线粒体细胞色素c释放,抑制Caspase-3激活[6][4]。
- 与Bax平衡:Bcl-2/Bax比值决定细胞命运,抗体可定量检测该比值变化[7][3][8]。
2. 信号通路交互作用
- PI3K/AKT/mTOR通路:Bcl-2通过抑制PTEN增强AKT活性,促进细胞存活[1][6][9]。
- 自噬调控:Bcl-2与Beclin-1结合抑制自噬,抗体用于验证其相互作用[7]。
三、临床应用
1. 肿瘤诊断与预后
- 生物标志物:Bcl-2高表达提示胃癌、胰腺癌不良预后[10][11]。
- 耐药性监测:在结直肠癌中,Bcl-2/Bax失衡与顺铂耐药相关[2][12]。
2. 治疗靶点验证
- 药物敏感性:蒲公英提取物通过下调Bcl-2增强食管癌对顺铂敏感性[2]。
- 中药干预:杜仲木质素通过降低Bcl-2表达抑制肾系膜细胞增殖[13]。
四、未来展望
1. 技术创新
- 纳米抗体开发:提高穿透性以用于活体成像[14]。
- 多组学整合:结合单细胞测序解析Bcl-2亚细胞定位动态[16]。
2. 临床转化方向
- 联合疗法:Bcl-2抑制剂(如Venetoclax)与免疫检查点抑制剂联用[10]。
- 代谢疾病应用:探索其在糖尿病心肌病氧化应激中的作用[9]。
结语
Bcl-2兔多克隆抗体(货号:APRab07501)是凋亡机制研究的核心工具,其应用已拓展至肿瘤、神经退行性疾病及代谢领域。未来需深化其临床转化,并开发高特异性衍生抗体以推动精准医疗发展。
参考文献
1. Pyrroline-5-Carboxylate Reductase-2 Promotes Colorectal Cancer Progression via Activating PI3K/AKT/mTOR Pathway. Yin F, et al. 2021 Sep 1.
2. Dandelion Seed Extract Affects Tumor Progression and Enhances the Sensitivity of Cisplatin in Esophageal Squamous Cell Carcinoma. Li Y, et al. 2022 May 20.
3. Cyclovirobuxine D inhibits colorectal cancer tumorigenesis via the CTHRC1-AKT/ERK-Snail signaling pathway. Jiang F, et al. 2020 Apr 6.
4. Gong J, et al. Lentiviral Vector-Mediated SHC3 Silencing Exacerbates Oxidative Stress Injury in Nigral Dopamine Neurons. 2018 Sep 2.
5. Bcl-2 Rabbit Polyclonal Antibody说明书.武汉恩玑生命科技有限公司.
6. Liraglutide improves cognitive impairment via the AMPK and PI3K/Akt signaling pathways in type 2 diabetic rats. Yang Y, et al. 2018 Jun 13.
7. Qiliqiangxin reduced cardiomyocytes apotosis and improved heart function in infarcted heart through Pink1/Parkin -mediated mitochondrial autophagy. Zhou J, et al. BMC Complement Med Ther. 2020 Jul 2;20(1):203. [PMID: 32615967]
8. TC2N, a novel oncogene, accelerates tumor progression by suppressing p53 signaling pathway in lung cancer. Hao XL, et al. Cell Death Differ. 2019 Jul;26(7):1235-1250. [PMID: 30254375]
9. Baicalein Protects Rats with Diabetic Cardiomyopathy Against Oxidative Stress via PI3K/AKT Pathway. Ma L, et al. 2018 Aug 8.
10. Prohibitin (PHB) as a Novel Prognostic Marker in Pancreatic Cancer. Wang W, et al. 2018 Sep 1.
11. Proteasome Inhibition Impairs Caspase-8 Activation upon TRAIL Signaling. Laussmann MA, et al. 2012 Mar 2.
12. Mitochondrial fission factor promotes cisplatin resistance in hepatocellular carcinoma. Li X, et al. 2022 Mar 1.
13. Eucommia ulmoides Oliv. Lignans Inhibit Angiotensin II-Stimulated Proliferation in Rat Mesangial Cells. Jing X, et al. Evidence-Based Complementary and Alternative Medicine. 2015 Jun 10.
14. Modulation of miR-192/NF-κB/ TGF-β/ E-cadherin by thymoquinone protects against diethylnitrosamine /carbon tetrachloride hepatotoxicity. Ashour H, et al. Physiol Int. 2022 Aug 12. [PMID: 36001412]
15. Spondin 2 promotes the proliferation, migration and invasion of gastric cancer cells. Lu H, et al. J Cell Mol Med. 2020 Jan;24(1):98-113. [PMID: 31691494]